Skip to main content
. 2008 Dec 15;53(3):869–875. doi: 10.1128/AAC.00868-08

TABLE 1.

Baseline patient characteristics

Characteristic No. (%) of patients with characteristic
Single dose of caspofungin (25 mg/m2) (n = 6) Multiple doses of caspofungin (25 mg/m2) (n = 12) Total (n = 18)
Gender
    Male 3 (50.0) 9 (75.0) 12 (66.7)
    Female 3 (50.0) 3 (25.0) 6 (33.3)
Race
    American Indian or Alaska Native 0 (0.0) 1 (8.3) 1 (5.6)
    Asian 2 (33.3) 2 (16.7) 4 (22.2)
    Black, of African heritage 0 (0.0) 1 (8.3) 1 (5.6)
    Multiracial 4 (66.7) 8 (66.7) 12 (66.7)
Gestational age at birth (wk)
    <28 1 (16.7) 0 (0.0) 1 (5.6)
    28 to 31 4 (66.7) 4 (33.3) 8 (44.4)
    32 to 36 1 (16.7) 3 (25.0) 4 (22.2)
    >36 0 (0.0) 5 (41.7) 5 (27.8)
Chronological age (wk)
    ≤2 3 (50.0) 2 (16.7) 5 (27.8)
    3 to 4 0 (0.0) 7 (58.3) 7 (38.9)
    5 to 8 3 (50.0) 1 (8.3) 4 (22.2)
    9 to 12 0 (0.0) 2 (16.7) 2 (11.1)
    Mean 3.8 4.9 4.6
    Median 3.5 4.0 4.0
    Range 1-7 2-11 1-11
Weight at enrollment (kg)
    ≤1 2 (33.3) 2 (16.7) 4 (22.2)
    1.01 to 1.50 1 (16.7) 2 (16.7) 3 (16.7)
    1.51 to 2.00 1 (16.7) 1 (8.3) 2 (11.1)
    2.01 to 2.50 1 (16.7) 2 (16.7) 3 (16.7)
    >2.50 1 (16.7) 5 (41.7) 6 (33.3)
Invasive Candida infection
    Documented 2 (33.3) 6 (50.0) 8 (44.4)
    Highly suspected 4 (66.7) 6 (50.0) 10 (55.6)